Report date: 2026-11-10
Analysis focus
Provide a balanced, comprehensive analysis: fundamentals and valuation, the Wall Street view, technical posture, and the key forward risks and catalysts.
Summary
Findings (24)
Q3 2026 revenue was a record $267.8M, up 73% from $155.1M a year earlier, above the $250–265M guidance and the roughly $257M consensus; the GAAP net loss was $79.7M, or $(0.12) per share, against a consensus of $(0.07).
High confidenceThe company's 8-K Exhibit 99.1 reports revenue of $267,834K against $155,080K in the prior year and a net loss of $(79,677)K, or $(0.12) per share. MarketBeat reports the $(0.07) consensus and the $0.05 miss.
Backlog grew 52% in the quarter to a record $3.57B, covering 117 launches. Q4 2026 guidance calls for $270–290M of revenue and an adjusted EBITDA loss of $14–20M, while Neutron's first launch is now no earlier than 2027, after the Q2 report had targeted delivery to the launch pad in Q4 2026.
High confidenceThe Q3 8-K gives the backlog, the Q4 guidance ranges and the 'no earlier than 2027' Neutron wording. Secondary coverage says the slip followed the discovery of voids in the stage 1 tank forward dome, and that eight Neutron launches were booked at a $70M base price.
Two non-recurring charges, $21.3M of transaction costs and a $27.3M loss on extinguishment of debt, add up to about $48.6M, or about 61% of the Q3 GAAP net loss; without them the loss would be about $31M (analyst calculation), and adjusted EBITDA was $(18.0)M.
High confidenceThe 8-K reconciliation lists $21,340K of Q3 transaction costs, which secondary coverage links to the pending Iridium acquisition, a $27,259K loss on extinguishment of debt, a $2,444K gain on contingent consideration and adjusted EBITDA of $(18,047)K. The EPS miss therefore mostly reflects one-time items, but the business is still loss-making even after removing them.
At September 30, 2026, Rocket Lab held about $4.70B in cash and marketable securities against almost no debt: net convertible notes fell to $1.3M from $152.4M at December 31, 2025, and net long-term borrowings were $1.7M. Free cash flow is still negative, at about $(211)M for the first nine months of 2026 and $(325.6)M on a trailing twelve-month basis.
High confidenceThe 8-K balance sheet shows $4,447,665K of cash plus $256,184K of marketable securities. The nine-month cash flow statement shows operating cash flow of $(127,254)K and capex of $(84,185)K. The headline +$7.2M Q3 operating cash flow cannot be checked from the published tables. StockAnalysis lists $120.28M of total debt, which probably includes leases or an older period.
Compared with its peer Firefly Aerospace (FLY), Rocket Lab trades at about 2.9 times the EV/Sales multiple (34.75 vs 12.15) and about 3.1 times the P/B multiple (10.08 vs 3.30), even though both companies burned about $326M of free cash flow over the trailing twelve months.
High confidenceStockAnalysis data as of the Nov 9 close lists Firefly at a $4.07B market cap, $3.49B EV, 14.18 P/S, 12.15 EV/Sales and $(326.49)M TTM free cash flow, against Rocket Lab's $(325.62)M. Rocket Lab's premium reflects its much larger scale: $881.9M of TTM revenue against Firefly's $287.0M.
On the chart, RKLB is in a downtrend: the $58.86 close sits below its 50-day moving average ($62.45) and well below its 200-day moving average ($78.72), and is about 61% below its 52-week high of roughly $151. RSI is neutral at 51.39 and the 5-year beta is high at 3.18; the stock fell after hours on November 9 after rising 10.9% during the session.
Medium confidenceStockAnalysis provides the moving averages, RSI and beta. The 52-week range of about $37.57–$151.00 comes from aggregator quote pages, and the Motley Fool and Investing.com describe the Nov 9 session and the after-hours move. No sourced five-year valuation-multiple history was found, so this compares the stock only with its 52-week range.
Q4 2026 guidance is $270M–$290M revenue with an adjusted EBITDA loss of $14M–$20M, and the first Neutron launch has slipped to 'no earlier than 2027', a key forward risk because Neutron underpins much of the bull case.
High confidenceThe company release states the guidance ranges and the Neutron 'no earlier than 2027' timing. An earlier pre-earnings preview had expected the first flight in Q4 2026, so this is a further delay. A secondary article citing $170–180M Q4 guidance appears to be from 2025 and conflicts with the 8-K.
The stock sits below both its 50-day simple moving average (about $61.70) and its 200-day SMA (about $81.90), and the 50-day is well under the 200-day, which is a bearish trend setup; MarketBeat's November 2 figures ($64.23 and $79.93) show the same picture.
High confidenceAltIndex, as of Nov 5, 2026, gives a 50-day SMA of $61.70 and a 200-day SMA of $81.90, with EMAs of $59.20 and $70.40. MarketBeat's Nov 2 article gives $64.23 and $79.93. The falling 50-day average shows that the downtrend since mid-2026 has not reversed.
RKLB closed at $58.86 on November 9, 2026, giving a market cap of about $35.23B and an enterprise value of about $30.64B; trailing P/S is 39.94, forward P/S is 31.36, EV/Sales is 34.75 and P/B is 10.08, while trailing P/E and EV/EBITDA cannot be calculated because earnings and EBITDA are negative, and the company pays no dividend.
Medium confidenceStockAnalysis lists these multiples as of the Nov 9 close, using 598.46M shares. The Motley Fool shows the same $58.86 price with a lower $31.76B market cap, and Morningstar lists 639.41M shares and a 40.32 P/S as of Nov 6, so market cap depends on which share count is used. The listed forward P/E of 1,110.57 is not meaningful.
Wall Street remains positive overall, with a 'Moderate Buy' consensus and an average price target of about $102, roughly 73% above the $58.86 close, but targets have been coming down: Citizens JMP cut its target to $90 from $130 on October 16, 2026, and TD Cowen set $90 on October 15.
Medium confidenceMarketBeat reports an average target of $102.05 and lists the October target changes. Yahoo Finance shows a $102.15 average target, with a high of $150 and a low of $64. No November 2026 downgrade was found, and these targets were set before the earnings report.
Q3 2026 revenue was a record $267.8M, up 73% from $155.1M a year earlier, with backlog of about $3.57B (+52% since the end of Q2), but the GAAP net loss was $79.7M ($0.12 per share) and adjusted EBITDA was -$18.0M.
High confidenceRocket Lab's Nov 9, 2026 earnings release, filed with the SEC as Exhibit 99.1 to an 8-K, reports $267,834K revenue against $155,080K, a $3.57B backlog, a $(79,677)K net loss and $(18,047)K adjusted EBITDA. The non-GAAP gross margin was 38.4%; the GAAP gross margin works out to about 33.6%.
Q3 GAAP results include about $46M of non-recurring charges: $21.3M of transaction costs, mostly for the pending Iridium acquisition, and a $27.3M loss on extinguishment of debt, partly offset by a $2.4M contingent-consideration gain; the reported $7.2M positive operating cash flow in the quarter compares with $127.3M of operating cash used over nine months.
High confidenceThe release's non-GAAP reconciliation lists these items as excluded charges, and the nine-month cash flow statement shows $(127,254)K operating cash flow and $(84,185)K capex, which is about -$211M of free cash flow (calculated). So the single quarter of positive operating cash flow does not yet mean a sustained turn.
RKLB closed at $58.86 on November 9, 2026, about 13.4% above its $51.90 price on November 10, 2025, but roughly 61% below its 52-week high of $151.00.
Medium confidenceThe StockAnalysis daily history lists a $58.86 close on Nov 9, 2026. TIKR gives the price as $51.90 on Nov 10, 2025, and MarketBeat lists a 52-week range of $37.57 to $151.00. The 12-month return is calculated from these two aggregator prices, not taken from a primary source.
Price swings were extreme in early November 2026: the stock fell 12.2% to a $45.99 close on November 5, then rose 15.4% to $53.07 on November 6 and another 10.9% to $58.86 on November 9, which makes $45.99 near-term support and the $59–$64 zone (late-October highs and the 50-day SMA) near-term resistance.
Medium confidenceStockAnalysis lists closes of $52.37 (Nov 4), $45.99 (Nov 5), $53.07 (Nov 6), $58.86 (Nov 9) and $59.10 (Oct 29), and AltIndex names $45.99 as support. MarketBeat lists a beta of 3.15, which fits the size of these daily moves. The support and resistance levels come from these closes, not from any published analyst's levels.
Third-quarter 2026 results are a near-term catalyst with a disputed date (MarketBeat says November 9 after the close, Earnings Whispers says November 12). Consensus is $257.19M in revenue, roughly 66% above the $155.1M from a year earlier, and EPS of about -$0.067, against company guidance of $250M–$265M in revenue and an adjusted EBITDA loss of $17M–$23M.
Medium confidenceMarketBeat gives a Nov 9 report date, $257.19M revenue consensus, -$0.0674 EPS consensus, and Q2 2026 results (reported Aug 10) of $234.07M revenue, a beat, and -$0.08 EPS, a miss against -$0.06. Earnings Whispers lists Nov 12, and The Right Trader says Nov 9 was not confirmed. No Q3 2026 results were found as of this writing, so the +10.9% move on Nov 9 should not be attributed to earnings. No one-time items were identified to normalize.
The average 12-month price target is $102.15 and the median is $102.50, with a range from $64 to $150; against the Nov 9, 2026 close of $58.86, the average implies about 74% upside and the lowest target about 9% upside.
Medium confidenceStockanalysis.com gives the average, median, low and high targets and the $58.86 close (the upside figures are calculated from these). A MarketBeat snapshot from August 2026 showed a similar $110.29 average and the same $150 high from 22 analysts, so the average has drifted down since the summer.
Recent targets from named banks and brokers compared with the $58.86 close: Morgan Stanley reiterated Buy/Overweight at $105 on Nov 6, 2026 (+78%); Goldman Sachs kept Hold and cut its target from $75 to $67 on Oct 15, 2026 (+14%); Citizens JMP kept Buy but cut from $130 to $90 on Nov 4, 2026 (+53%); Cantor Fitzgerald reiterated Buy at $122 on Nov 4, 2026 (+107%).
Medium confidenceThe stockanalysis.com recent-actions table lists each firm, date, rating and target. Nasdaq's coverage confirms that Morgan Stanley's $105 target came from its January 2026 upgrade from Equal-Weight to Overweight. No current JPMorgan, Citi, Wells Fargo or Barclays targets turned up in the searches, and the only BofA data point ($60 Buy) is from late 2025.
Analyst actions in the last 90 days lean toward lower targets: Goldman cut by $8 and Citizens JMP by $40, while Morgan Stanley, Cantor and Needham ($120, Oct 16) held their targets; the searches found no upgrades or downgrades from a major bank in this period.
Medium confidenceThe dated actions from Oct 15 to Nov 6, 2026 on stockanalysis.com are all 'maintains', 'reiterates' or target cuts. The 2026 rating changes found in the searches (Morgan Stanley upgrade in January, KeyBanc downgrade in January, Citizens upgrade in April, Craig-Hallum upgrade in May) all fall outside the 90-day window.
The Wall Street consensus is 'Moderate Buy' (3 Strong Buy, 14 Buy, 5 Hold, 1 Sell) with an average price target of $102.05, roughly 73% above the $58.86 close; the gap suggests targets have not caught up with the price decline, and Bank of America trimmed its target to $110 from $115 on August 31.
Medium confidenceMarketBeat lists the rating split, the $102.05 average target, the BofA cut, a market cap of $32.75B, a P/E of -202.70 (not meaningful because earnings are negative) and a beta of 3.15. The implied upside is calculated against the StockAnalysis close. A comparison of valuation with a peer or with RKLB's 5-year history could not be sourced within this search budget.
Per S&P Global data shown on stockanalysis.com (updated Nov 6, 2026), 21 analysts cover RKLB with a consensus 'Buy' rating: 12 Strong Buy, 5 Buy, 4 Hold, 0 Sell and 0 Strong Sell.
Medium confidenceThe stockanalysis.com forecast page lists the November 2026 rating breakdown and the 21-analyst count. It is a secondary aggregator, and other aggregators report different analyst counts (Benzinga lists 27), so the breakdown depends on which coverage set is used.
At the Nov 9, 2026 close, RKLB had a $35.2B market cap, $30.6B enterprise value and an EV/Sales multiple of about 34.8x on $881.9M TTM revenue, and traded below its 50-day ($62.45) and 200-day ($78.72) moving averages with an RSI of 51 and a 5-year beta of 3.18.
Medium confidenceThe stockanalysis.com statistics page (secondary) lists these valuation and technical figures, and they check out (EV $30.64B ÷ TTM revenue $0.882B ≈ 34.7x). The price below both averages with a neutral RSI reads as a downtrend without oversold conditions; the searches did not return a peer multiple or 5-year valuation history, so those comparisons are not verified here.
RSI(14) is about 55, which is neutral (neither overbought nor oversold), and MACD(12,26) is about -1.7, so momentum has recovered from earlier oversold readings but has not turned clearly positive.
Medium confidenceAltIndex lists RSI(14) at 55, labeled neutral, and MACD at -1.7. An earlier cached version of the same page showed an oversold RSI with the price near $54, which suggests the reading rose with the bounce in early November. Indicator values from a single aggregator should be checked against a live chart.
The main fundamental reason for the de-rating is that Neutron's first launch was pushed from 2026 to 2027, after which KeyBanc cut its price target from $135 to $100 and the stock fell about 7.85% to around $59.
Medium confidenceThe Financial Modeling Prep market-news piece, as shown in search results, reports the KeyBanc cut, the delay to 2027 and the roughly 7.85% drop. The page returned 403 when fetched, so the exact date could not be confirmed, and the company's own 8-K or press release on the delay was not reviewed.
Most of the past six months has been a sharp decline: RKLB peaked near $143.20 on May 26, 2026, fell to about $85.01 by June 26 (RSI 34.48, 50-day SMA $105.81), and the current $58.86 is about 59% below that May peak.
Low confidenceThe June 26, 2026 trading note on HistoricalOptionData, as shown in search results, gives the $143.20 peak on 5/26, the $85.01 price, RSI 34.48, $90 resistance and $80 support. The page returned 404 when fetched directly, so these figures could not be checked. An exact 6-month return from November 10, 2025 could not be calculated because no close for that date was found.
Sources (24)
- https://www.sec.gov/Archives/edgar/data/0001819994/000181999426000073/rklb-11092026ex991.htmfundamentalsPrimary
- https://www.sec.gov/Archives/edgar/data/0001819994/000181999426000061/rklb-08102026ex991.htmfundamentalsPrimary
- https://stockanalysis.com/stocks/rklb/statistics/fundamentalsSecondary
- https://stockanalysis.com/stocks/fly/statistics/fundamentalsSecondary
- https://www.morningstar.com/stocks/xnas/rklb/quotefundamentalsSecondary
- https://www.fool.com/investing/2026/11/08/why-nov-9-could-be-a-huge-day-for-rocket-lab-inves/fundamentalsSecondary
- https://www.marketbeat.com/instant-alerts/earnings-rocket-lab-nasdaq-rklb-posts-quarterly-earnings-results-misses-expectations-by-005-eps-2026-11-09/fundamentalsSecondary
- https://finance.yahoo.com/quote/RKLB/fundamentalsSecondary
- https://www.benzinga.com/quote/RKLB/analyst-ratingsfundamentalsSecondary
- https://www.investing.com/news/transcripts/earnings-call-transcript-rocket-lab-beats-revenue-in-q3-2026-stock-swings-lower-after-hours-93CH-5013696fundamentalsSecondary
- https://finance.biggo.com/news/US_RKLB_2026-11-09fundamentalsSecondary
- https://www.heygotrade.com/en/us-stock/rklb/fundamentalsSecondary
- https://stockanalysis.com/stocks/rklb/forecast/analyst_targetsSecondary
- https://www.marketbeat.com/stocks/NASDAQ/RKLB/forecast/analyst_targetsSecondary
- https://www.nasdaq.com/articles/morgan-stanley-upgrades-rocket-lab-rklbanalyst_targetsSecondary
- https://finviz.com/news/413866/rocket-labs-q3-report-puts-neutrons-narrowing-launch-window-ahead-of-record-revenueanalyst_targetsSecondary
- https://stockanalysis.com/stocks/rklb/history/technicalsSecondary
- https://altindex.com/ticker/rklb/technical-analysistechnicalsSecondary
- https://www.marketbeat.com/instant-alerts/upcoming-rocket-lab-rklb-set-to-release-earnings-on-monday-2026-11-02/technicalsSecondary
- https://www.tikr.com/blog/rocket-lab-nasdaq-rklb-stock-surges-on-q3-revenue-and-earnings-beattechnicalsSecondary
- https://historicaloptiondata.com/?p=64508technicalsUnreliable
- https://site.financialmodelingprep.com/market-news/rocket-lab-rklb-keybanc-price-target-neutron-launch-delaytechnicalsSecondary
- https://www.earningswhispers.com/stocks/RKLBtechnicalsSecondary
- https://therighttrader.com/earnings-calendar/rklbtechnicalsSecondary
Caveats
Time sensitivity: this report is as of November 10, 2026, one day after the Q3 release and the after-hours move. Prices, technical readings and analyst targets may change quickly, and analyst revisions made after the earnings report are not captured; every quoted target was set before the release [10]. Superseded data: finding [15] is a stale pre-earnings snapshot. It says no Q3 results were available and lists a disputed report date, and findings [1] and [11] from the 8-K replace it. Conflicts between sources: the Citizens JMP cut is dated October 16 in [10] but November 4 in [17]. Morgan Stanley's $105 target is listed as reiterated on November 6 but dates back to a January 2026 upgrade [17]. KeyBanc's cut to $100 is undated because its source page returned 403 [23]. Analyst counts and rating splits differ by aggregator: 23 on MarketBeat, 21 on StockAnalysis/S&P Global and 27 on Benzinga [19][20]. Moving averages differ by source and date: 50-day $61.70–$64.23 and 200-day $78.72–$81.90 [6][8][21], and RSI is 51.39 or 55 depending on the source [6][22]. Market cap ranges from $31.76B to $35.23B depending on the share count [9][19]. One-time charges total $48.6M gross or about $46M net of a $2.4M contingent-consideration gain [3][12]. The ex-items loss of about $31M, the implied upside figures and the 12-month return are analyst calculations, not reported figures [3][13][16]. Data quality: the +$7.2M Q3 operating cash flow cannot be checked [4]. StockAnalysis's $120.28M total debt probably includes leases or an older period, so it is not comparable with the 8-K [4]. A secondary article citing $170–180M Q4 guidance appears to be from 2025 [7]. The link between the transaction costs and Iridium, the tank-dome void explanation and the eight $70M Neutron bookings come from secondary sources [2][3]. Finding [24] is low confidence because its source returned 404. Support and resistance levels are derived from daily closes, not from published analyst work [14]. Technical figures come mainly from single aggregators [21][22]. Gaps: no sourced 5-year valuation-multiple history was found, so the historical comparison uses only the 52-week range [6][19]. The peer comparison uses one company, Firefly [5]. Not covered: segment mix (launch vs space systems), Iridium deal terms and possible dilution, insider activity, short interest and options positioning, competition (for example SpaceX), and government or defense budget exposure. This report is balanced evidence, not investment advice or a buy, sell or hold recommendation.
This report is for informational purposes only and is not investment advice. No buy / sell / hold recommendation is made or implied.
More research reports
Recent reports from the same pipeline. See all examples